MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters b...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.845969/full |
| _version_ | 1828773956544364544 |
|---|---|
| author | Robbert Boudewijns Patricia Pérez Patricia Pérez Adrián Lázaro-Frías Adrián Lázaro-Frías Dominique Van Looveren Thomas Vercruysse Hendrik Jan Thibaut Birgit Weynand Lotte Coelmont Johan Neyts David Astorgano Dolores Montenegro Eugenia Puentes Esteban Rodríguez Kai Dallmeier Mariano Esteban Juan García-Arriaza Juan García-Arriaza |
| author_facet | Robbert Boudewijns Patricia Pérez Patricia Pérez Adrián Lázaro-Frías Adrián Lázaro-Frías Dominique Van Looveren Thomas Vercruysse Hendrik Jan Thibaut Birgit Weynand Lotte Coelmont Johan Neyts David Astorgano Dolores Montenegro Eugenia Puentes Esteban Rodríguez Kai Dallmeier Mariano Esteban Juan García-Arriaza Juan García-Arriaza |
| author_sort | Robbert Boudewijns |
| collection | DOAJ |
| description | To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials. |
| first_indexed | 2024-12-11T15:12:43Z |
| format | Article |
| id | doaj.art-d871bff5a71f4dbfb6749099aa0eb66a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T15:12:43Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d871bff5a71f4dbfb6749099aa0eb66a2022-12-22T01:00:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-03-011310.3389/fimmu.2022.845969845969MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in HamstersRobbert Boudewijns0Patricia Pérez1Patricia Pérez2Adrián Lázaro-Frías3Adrián Lázaro-Frías4Dominique Van Looveren5Thomas Vercruysse6Hendrik Jan Thibaut7Birgit Weynand8Lotte Coelmont9Johan Neyts10David Astorgano11Dolores Montenegro12Eugenia Puentes13Esteban Rodríguez14Kai Dallmeier15Mariano Esteban16Juan García-Arriaza17Juan García-Arriaza18KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, BelgiumDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, SpainCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, SpainDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, SpainCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, SpainKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), Leuven, BelgiumKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), Leuven, BelgiumKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), Leuven, BelgiumKU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, Leuven, BelgiumKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, BelgiumKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, BelgiumDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, SpainBiofabri, Pontevedra, SpainBiofabri, Pontevedra, SpainBiofabri, Pontevedra, SpainKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, BelgiumDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, SpainDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, SpainCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, SpainTo control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.https://www.frontiersin.org/articles/10.3389/fimmu.2022.845969/fullSARS-CoV-2COVID-19MVA vaccinespikehamstersimmunogenicity |
| spellingShingle | Robbert Boudewijns Patricia Pérez Patricia Pérez Adrián Lázaro-Frías Adrián Lázaro-Frías Dominique Van Looveren Thomas Vercruysse Hendrik Jan Thibaut Birgit Weynand Lotte Coelmont Johan Neyts David Astorgano Dolores Montenegro Eugenia Puentes Esteban Rodríguez Kai Dallmeier Mariano Esteban Juan García-Arriaza Juan García-Arriaza MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters Frontiers in Immunology SARS-CoV-2 COVID-19 MVA vaccine spike hamsters immunogenicity |
| title | MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters |
| title_full | MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters |
| title_fullStr | MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters |
| title_full_unstemmed | MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters |
| title_short | MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters |
| title_sort | mva cov2 s vaccine candidate neutralizes distinct variants of concern and protects against sars cov 2 infection in hamsters |
| topic | SARS-CoV-2 COVID-19 MVA vaccine spike hamsters immunogenicity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.845969/full |
| work_keys_str_mv | AT robbertboudewijns mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT patriciaperez mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT patriciaperez mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT adrianlazarofrias mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT adrianlazarofrias mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT dominiquevanlooveren mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT thomasvercruysse mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT hendrikjanthibaut mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT birgitweynand mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT lottecoelmont mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT johanneyts mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT davidastorgano mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT doloresmontenegro mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT eugeniapuentes mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT estebanrodriguez mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT kaidallmeier mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT marianoesteban mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT juangarciaarriaza mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters AT juangarciaarriaza mvacov2svaccinecandidateneutralizesdistinctvariantsofconcernandprotectsagainstsarscov2infectioninhamsters |